Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'Beamion PANTUMOR 1: A Phase II, multicentre, multicohort, open-label trial to evaluate the effica... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'An open-label, multi-center, phase I/Ib study of IEV407 as a single agent and in combination with... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safe... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Inves... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) ... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo i... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'Safety, immunogenicity and efficacy of low dose Nivolumab in adults living with HIV on antiretrov... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Stud... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'Antigen Targeted T cell therapy for Relapsed/Refractory B cell Lymphomas'. The following are the ... Read More